STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025

Reuters · 01/07 12:00

Please log in to view news